{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:45:49Z","timestamp":1789926349375,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung eV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.parkreldis.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:45:08Z","timestamp":1613562308000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-8439","authenticated-orcid":false,"given":"Chi-un","family":"Choe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lezius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"P\u00f6tter-Nerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gerloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3597-6276","authenticated-orcid":false,"given":"Edzard","family":"Schwedhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2021.02.007_bib1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.25564","article-title":"Associations between cerebrovascular risk factors and Parkinson disease","volume":"86","author":"Kummer","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.007_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the de novo Parkinson cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2021.02.007_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022854","article-title":"Serum cholesterol and the progression of Parkinson's disease: results from DATATOP","volume":"6","author":"Huang","year":"2011","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.parkreldis.2021.02.007_bib4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/mds.27413","article-title":"Higher serum cholesterol and decreased Parkinson's disease risk: a statin-free cohort study","volume":"33","author":"Rozani","year":"2018","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.02.007_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mds.26152","article-title":"Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study","volume":"30","author":"Huang","year":"2015","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2021.02.007_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.27006","article-title":"Statins may facilitate Parkinson's disease: insight gained from a large, national claims database","volume":"32","author":"Liu","year":"2017","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2021.02.007_bib7","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/mds.26290","article-title":"Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients","volume":"30","author":"Swanson","year":"2015","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2021.02.007_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.26022","article-title":"Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype","volume":"30","author":"Swanson","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.02.007_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.23872","article-title":"Plasma apolipoprotein A1 as a biomarker for Parkinson disease","volume":"74","author":"Qiang","year":"2013","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2021.02.007_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mds.27888","article-title":"Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort","volume":"35","author":"Lawton","year":"2020","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2021.02.007_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/CIRCRESAHA.119.314929","article-title":"Lipids, apolipoproteins, and the risk of Parkinson disease","volume":"125","author":"Fang","year":"2019","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.parkreldis.2021.02.007_bib12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/mds.28129","article-title":"Subclinical cardiac microdamage, motor severity, and cognition in Parkinson's disease","volume":"35","author":"Choe","year":"2020","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2021.02.007_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10654-019-00577-4","article-title":"Rationale and design of the Hamburg city health study","volume":"35","author":"Jagodzinski","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.parkreldis.2021.02.007_bib14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jnnp.2011.240366","article-title":"The natural history of treated Parkinson's disease in an incident, community based cohort","volume":"82","author":"Evans","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2021.02.007_bib15","article-title":"When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis","author":"Marsili","year":"2020","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2021.02.007_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.870110304","article-title":"Clinical course of patients with idiopathic Parkinson's disease","volume":"11","author":"Roos","year":"1996","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2021.02.007_bib17","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2021.02.007_bib18","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.parkreldis.2021.02.007_bib19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horvath","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4\u20136","key":"10.1016\/j.parkreldis.2021.02.007_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000496454","article-title":"Responsiveness to change of the montreal cognitive assessment, mini-mental state examination, and SCOPA-cog in non-demented patients with Parkinson's disease","volume":"47","author":"Faust-Socher","year":"2019","journal-title":"Dement. Geriatr. Cognit. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2021.02.007_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/mds.27521","article-title":"Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment","volume":"33","author":"Huang","year":"2018","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2021.02.007_bib22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ana.10220","article-title":"Association between high-density lipoprotein and cognitive impairment in the oldest old","volume":"51","author":"van Exel","year":"2002","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2021.02.007_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JGP.0b013e318211819b","article-title":"Association between cognitive function and plasma lipids of the elderly after controlling for apolipoprotein E genotype","volume":"20","author":"Yasuno","year":"2012","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"12","key":"10.1016\/j.parkreldis.2021.02.007_bib24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/hmg\/ddz038","article-title":"Cellular alpha-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons","volume":"28","author":"Zambon","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"19","key":"10.1016\/j.parkreldis.2021.02.007_bib25","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/hmg\/ddx269","article-title":"NCEH-1 modulates cholesterol metabolism and protects against alpha-synuclein toxicity in a C. elegans model of Parkinson's disease","volume":"26","author":"Zhang","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.02.007_bib26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-4159.2006.04017.x","article-title":"Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy","volume":"98","author":"Bar-On","year":"2006","journal-title":"J. Neurochem."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:17Z","timestamp":1761178877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":26,"alternative-id":["S1353802021000481"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.007","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}